Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075344 | 1.00 | ERBB2 (0.67) | ERBB2 | |
| SCHEMBL5749646 | 0.89 | ERBB2 (0.61) | ERBB2 | |
| SCHEMBL5749650 | 0.89 | ERBB2 (0.61) | ERBB2 | |
| SCHEMBL4499821 | 0.86 | ERBB2 (0.65) | ERBB2 | |
| SCHEMBL4499820 | 0.86 | ERBB2 (0.65) | ERBB2 | |
| SCHEMBL5749396 | 0.84 | ERBB2 (0.62) | ERBB2 | |
| SCHEMBL5749401 | 0.84 | ERBB2 (0.62) | ERBB2 | |
| SCHEMBL4154802 | 0.82 | ERBB2 (0.49) | ERBB2 | |
| SCHEMBL4154806 | 0.82 | ERBB2 (0.49) | ERBB2 | |
| SCHEMBL22397906 | 0.82 | ERBB2 (0.46) | ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090093491-A1 | Diazine Azole Derivatives, Their Manufacture and Use as Pharmaceutical | JENNI WOLFGANG | 2009-04-09 | — | — | US | disclosed |
| EP-1934210-A1 | DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039226-A1 | DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| CN-1934106-A | Novel diazine derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | CN | disclosed |
| EP-1758897-A1 | NOVEL DIAZINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| US-7179812-B2 | Diazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2005097785-A1 | NOVEL DIAZINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222228-A1 | Novel diazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-10-06 | — | — | US | disclosed |
| US-20040106803-A1 | Production method of 1-substituted-1,2,3-triazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | US | disclosed |
| US-6743924-B2 | EFFICIENT, HIGH YEILD SYNTHESIS OF TYROSINE KINASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| EP-1310491-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-1,2,3-TRIAZOLE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-20030069419-A1 | Method for producing 1-substituted-1,2,3- triazole derivative | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | ERBB2 835/4885 |
| US-20050222228-A1 | Novel diazine derivatives | BRCA1, SLC5A1, PDHA1 | ERBB2 1298/4885 |
| US-20040106803-A1 | Production method of 1-substituted-1,2,3-triazole derivatives | ABL1, ROS1, ADH1A | ERBB2 78/4885 |
| US-20030069419-A1 | Method for producing 1-substituted-1,2,3- triazole derivative | ABL1, YES1, MAP3K1 | ERBB2 77/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | ERBB2 842/4885 |
| US-20090093491-A1 | Diazine Azole Derivatives, Their Manufacture and Use as Pharmaceutical | CYP3A5, CYP3A7, CYP3A43 | ERBB2 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.